Literature DB >> 23590594

Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology.

A C Palei1, F T Spradley, J P Warrington, E M George, J P Granger.   

Abstract

Despite being one of the leading causes of maternal death and a major contributor of maternal and perinatal morbidity, the mechanisms responsible for the pathogenesis of pre-eclampsia have yet to be fully elucidated. However, it is evident that this is a complex disorder involving multiple organ systems, and by using integrative approaches, enormous progress has been made towards understanding the pathophysiology of pre-eclampsia. Growing evidence supports the concept that the placenta plays a central role in the pathogenesis of pre-eclampsia and that reduced uteroplacental perfusion, which develops as a result of abnormal cytotrophoblast invasion of spiral arterioles, triggers the cascade of events leading to the maternal disorder. Placental ischaemia leads to release of soluble placental factors, many of which are classified as anti-angiogenic or pro-inflammatory. Once these ischaemic placental factors reach the maternal circulation, they cause widespread activation and dysfunction of the maternal vascular endothelium that results in enhanced formation of endothelin-1 and superoxide, increased vascular sensitivity to angiotensin II and decreased formation of vasodilators such as nitric oxide. This review highlights these links between placental ischaemia, maternal endothelial activation and renal dysfunction in the pathogenesis of hypertension in pre-eclampsia.
© 2013 Scandinavian Physiological Society. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23590594      PMCID: PMC3687012          DOI: 10.1111/apha.12106

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  70 in total

1.  Endothelin receptor antagonist has limited access to the fetal compartment during chronic maternal administration late in pregnancy.

Authors:  Larry G Thaete; Saira Khan; Sylvia Synowiec; Brian D Dayton; Joy Bauch; Mark G Neerhof
Journal:  Life Sci       Date:  2012-03-03       Impact factor: 5.037

Review 2.  Immunology of pre-eclampsia.

Authors:  Christopher W G Redman; Ian L Sargent
Journal:  Am J Reprod Immunol       Date:  2010-03-23       Impact factor: 3.886

Review 3.  Fetal-maternal conflict, trophoblast invasion, preeclampsia, and the red queen.

Authors:  Robert Pijnenborg; Lisbeth Vercruysse; Myriam Hanssens
Journal:  Hypertens Pregnancy       Date:  2008       Impact factor: 2.108

4.  Evidence for peroxynitrite formation in the vasculature of women with preeclampsia.

Authors:  A M Roggensack; Y Zhang; S T Davidge
Journal:  Hypertension       Date:  1999-01       Impact factor: 10.190

Review 5.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

6.  Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats.

Authors:  Babbette LaMarca; Gerd Wallukat; Mayte Llinas; Florian Herse; Ralf Dechend; Joey P Granger
Journal:  Hypertension       Date:  2008-10-13       Impact factor: 10.190

7.  Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats.

Authors:  Mona Sedeek; Jeffrey S Gilbert; Babbette B LaMarca; Myssara Sholook; Derrick L Chandler; Yuping Wang; Joey P Granger
Journal:  Am J Hypertens       Date:  2008-07-31       Impact factor: 2.689

8.  Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1.

Authors:  Babbette LaMarca; Marc Parrish; Lillian Fournier Ray; Sydney R Murphy; Lyndsay Roberts; Porter Glover; Gerd Wallukat; Katrin Wenzel; Kathy Cockrell; James N Martin; Michael J Ryan; Ralf Dechend
Journal:  Hypertension       Date:  2009-08-24       Impact factor: 10.190

Review 9.  Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia.

Authors:  S W Walsh
Journal:  Semin Reprod Endocrinol       Date:  1998

10.  Systemic inflammatory priming in normal pregnancy and preeclampsia: the role of circulating syncytiotrophoblast microparticles.

Authors:  Sarah J Germain; Gavin P Sacks; Suren R Sooranna; Suren R Soorana; Ian L Sargent; Christopher W Redman
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

View more
  66 in total

Review 1.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

2.  Continued Investigation Into 17-OHPC: Results From the Preclinical RUPP Rat Model of Preeclampsia.

Authors:  Lorena M Amaral; Jessica L Faulkner; Jamil Elfarra; Denise C Cornelius; Mark W Cunningham; Tarek Ibrahim; Venkata Ramana Vaka; Jessica McKenzie; Babbette LaMarca
Journal:  Hypertension       Date:  2017-10-30       Impact factor: 10.190

3.  The Dahl salt-sensitive rat is a spontaneous model of superimposed preeclampsia.

Authors:  Ellen E Gillis; Jan M Williams; Michael R Garrett; Jennifer N Mooney; Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-04-22       Impact factor: 3.619

4.  Integrating Acupuncture for Preeclampsia with Severe Features and HELLP Syndrome in a High-Risk Antepartum Care Setting.

Authors:  Zena Kocher; Valerie Hobbs
Journal:  Med Acupunct       Date:  2019-12-13

5.  Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.

Authors:  M R Luizon; A C T Palei; V A Belo; L M Amaral; R Lacchini; G Duarte; R C Cavalli; V C Sandrim; J E Tanus-Santos
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

Review 6.  Fetal programming and cardiovascular pathology.

Authors:  Barbara T Alexander; John Henry Dasinger; Suttira Intapad
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

Review 7.  Inhibition of ENaC by endothelin-1.

Authors:  Andrey Sorokin; Alexander Staruschenko
Journal:  Vitam Horm       Date:  2015-03-06       Impact factor: 3.421

8.  Chronic hyperleptinemia results in the development of hypertension in pregnant rats.

Authors:  Ana C Palei; Frank T Spradley; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-03-11       Impact factor: 3.619

9.  Sodium hydrosulfide prevents hypertension and increases in vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 in hypertensive pregnant rats.

Authors:  Jose Sergio Possomato-Vieira; Victor Hugo Gonçalves-Rizzi; Tamiris Uracs Sales Graça; Regina Aparecida Nascimento; Carlos A Dias-Junior
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-12       Impact factor: 3.000

10.  Placental origins of adverse pregnancy outcomes: potential molecular targets: an Executive Workshop Summary of the Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Authors:  John V Ilekis; Ekaterini Tsilou; Susan Fisher; Vikki M Abrahams; Michael J Soares; James C Cross; Stacy Zamudio; Nicholas P Illsley; Leslie Myatt; Christine Colvis; Maged M Costantine; David M Haas; Yoel Sadovsky; Carl Weiner; Erik Rytting; Gene Bidwell
Journal:  Am J Obstet Gynecol       Date:  2016-03-10       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.